Sanofi-Aventis is mapping out plans to leave Genzyme's orphan drug business with a "large extent of autonomy," says Hanspeter Spek, global operations president for the big pharma company. But anywhere Genzyme's operations overlap with Sanofi, he adds, they'll look for places to cut. Underscoring the certainty that any kind of redundant positions will face the budget axe, Genzyme CEO Henri Termeer (photo) tells the Boston Herald that it's likely that administrative cuts are on the way, but added that new jobs can be created in R&D and manufacturing, where Sanofi will look to expand on the company's unique abilities. Story | Report